No Data
No Data
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Raises Target Price to $110
Buy Rating on Merus: Promising Potential of Petosemtamab in Combination With PD-1 Therapy for Head and Neck Cancer
Merus (MRUS) Gets a Buy From Citi
B of A Securities Maintains Buy on Merus, Lowers Price Target to $70
BofA Securities Maintains Merus(MRUS.US) With Buy Rating
Stifel Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $93
Unlock the Full List